RT Journal Article
SR Electronic
T1 The Ultra Fit Community Mask - Toward Maximal Respiratory Protection via Personalized Face Fit
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.01.21259428
DO 10.1101/2021.07.01.21259428
A1 Chulho Hyun
A1 Mark Martin Jensen
A1 Kisuk Yang
A1 James C. Weaver
A1 Xiaohong Wang
A1 Yoshimasa Kudo
A1 Steven J. Gordon
A1 Jeffrey M. Karp
A1 Anthony E. Samir
YR 2021
UL http://medrxiv.org/content/early/2021/07/06/2021.07.01.21259428.abstract
AB Effective masking policies to prevent the spread of airborne infections depend on public access to masks with high filtration efficacy. However, poor face-fit is almost universally present in pleated multilayer disposable face masks, severely limiting both individual and community respiratory protection. We developed a set of simple mask modifications to mass-manufactured disposable masks, the most common type of mask used by the public, that dramatically improves both their personalized fit and performance in a low-cost and scalable manner. These modifications comprise a user-moldable full mask periphery wire, integrated earloop tension adjusters, and an inner flange to trap respiratory droplets. We demonstrate that these simple design changes improves quantitative fit factor by 320%, triples the level of protection against aerosolized droplets, and approaches the model efficacy of N95 respirators in preventing the community spread of COVID-19, for an estimated additional cost of less than 5 cents per mask with automated production.Teaser A personalizable, low-cost mask improves facial fit, reduces user exposure, and decreases spread of contagious aerosols.Competing Interest StatementThe UFM technology described herein has been optioned to Katharos Labs, a company in which Jeffrey M. Karp, Anthony Samir, Steven J. Gordon, and Chulho Hyun hold equity. J.M.K. has been a paid consultant and or equity holder for multiple companies including Katharos Labs (listed here https://www.karplab.net/team/jeff-karp). The interests of J.M.K. were reviewed and are subject to a management plan overseen by his institution in accordance with its conflict of interest policies.Funding StatementWe acknowledge funding from Katharos Laboratories LLC. We would also like to thank all of the volunteers, Harvard University undergraduate students, the Harvard Natural Sciences Lecture Demonstration team, Harry Miller Co., early users for their design feedback (Alice, David, Nick, and Laura), and the Mass General Brigham Center for Covid Innovation, Susan Goldsmith, and Max Miller for their contributions. This work was also supported by the Incheon National University Research Grant in 2021 to KY. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mass General Brigham IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data described in this manuscript are available through request to the corresponding authors.